Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Synthesis, in vitro and in vivo characterization of (64)Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands.

Alidori S, Gioia Lobbia G, Papini G, Pellei M, Porchia M, Refosco F, Tisato F, Lewis JS, Santini C.

J Biol Inorg Chem. 2008 Feb;13(2):307-15. Epub 2007 Nov 27.

PMID:
18043951
2.

Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA): cytotoxic activity evaluation of a series of water soluble Cu(I) derivatives containing PTA, PTAH and mPTA ligands.

Porchia M, Benetollo F, Refosco F, Tisato F, Marzano C, Gandin V.

J Inorg Biochem. 2009 Dec;103(12):1644-51. doi: 10.1016/j.jinorgbio.2009.09.005. Epub 2009 Sep 13.

PMID:
19822369
3.

Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.

Marzano C, Pellei M, Colavito D, Alidori S, Lobbia GG, Gandin V, Tisato F, Santini C.

J Med Chem. 2006 Dec 14;49(25):7317-24.

PMID:
17149861
4.

Cu(I) complexes bearing the new sterically demanding and coordination flexible tris(3-phenyl-1-pyrazolyl)methanesulfonate ligand and the water-soluble phosphine 1,3,5-triaza-7-phosphaadamantane or related ligands.

Wanke R, Smoleński P, da Silva MF, Martins LM, Pombeiro AJ.

Inorg Chem. 2008 Nov 3;47(21):10158-68. doi: 10.1021/ic801254b. Epub 2008 Oct 8.

PMID:
18841929
5.

198Au-labeled hydroxymethyl phosphines as models for potential therapeutic pharmaceuticals.

Berning DE, Katti KV, Volkert WA, Higginbotham CJ, Ketring AR.

Nucl Med Biol. 1998 Aug;25(6):577-83.

PMID:
9751426
6.

Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET.

Lewis JS, Dearling JL, Sosabowski JK, Zweit J, Carnochan P, Kelland LR, Coley HM, Blower PJ.

Eur J Nucl Med. 2000 Jun;27(6):638-46.

PMID:
10901449
7.

Syntheses, in vitro and in vivo characterization of a 99mTc-(I)-tricarbonyl-benzylamino-dihydroxymethyl phosphine (NP(2)) chelate.

Kothari KK, Raghuraman K, Pillarsetty NK, Hoffman TJ, Owen NK, Katti KV, Volkert WA.

Appl Radiat Isot. 2003 May;58(5):543-9.

PMID:
12735970
8.

In vitro antitumor activity of the water soluble copper(I) complexes bearing the tris(hydroxymethyl)phosphine ligand.

Marzano C, Gandin V, Pellei M, Colavito D, Papini G, Lobbia GG, Del Giudice E, Porchia M, Tisato F, Santini C.

J Med Chem. 2008 Feb 28;51(4):798-808. doi: 10.1021/jm701146c. Epub 2008 Feb 6.

PMID:
18251492
9.

In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands.

Santini C, Pellei M, Papini G, Morresi B, Galassi R, Ricci S, Tisato F, Porchia M, Rigobello MP, Gandin V, Marzano C.

J Inorg Biochem. 2011 Feb;105(2):232-40. doi: 10.1016/j.jinorgbio.2010.10.016. Epub 2010 Nov 5.

PMID:
21194623
10.

Synthesis, characterization and biological evaluation of [188Re(N)(cys ∼)(PNP)]+/0 mixed-ligand complexes as prototypes for the development of 188Re(N)-based target-specific radiopharmaceuticals.

Thieme S, Agostini S, Bergmann R, Pietzsch J, Pietzsch HJ, Carta D, Salvarese N, Refosco F, Bolzati C.

Nucl Med Biol. 2011 Apr;38(3):399-415. doi: 10.1016/j.nucmedbio.2010.09.006. Epub 2010 Dec 3.

PMID:
21492789
11.

64Cu-Labeled triphenylphosphonium and triphenylarsonium cations as highly tumor-selective imaging agents.

Wang J, Yang CT, Kim YS, Sreerama SG, Cao Q, Li ZB, He Z, Chen X, Liu S.

J Med Chem. 2007 Oct 18;50(21):5057-69. Epub 2007 Sep 15.

PMID:
17867662
12.

In vitro and in vivo characterization of a 99mTc complex with tris(hydroxymethyl)phosphine (THP).

Berning DE, Katti KV, Singh PR, Higgenbotham C, Reddy VS, Volkert WA.

Nucl Med Biol. 1996 Jul;23(5):617-22.

PMID:
8905826
13.

Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.

McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS.

Nucl Med Biol. 2005 Feb;32(2):147-56.

PMID:
15721760
14.

MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.

Parry JJ, Andrews R, Rogers BE.

Breast Cancer Res Treat. 2007 Jan;101(2):175-83. Epub 2006 Jul 13.

PMID:
16838112
15.

Synthesis and evaluation of copper radiopharmaceuticals with mixed bis(thiosemicarbazone) ligands.

Ackerman LJ, West DX, Mathias CJ, Green MA.

Nucl Med Biol. 1999 Jul;26(5):551-4.

PMID:
10473194
16.

64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors.

Wei L, Easmon J, Nagi RK, Muegge BD, Meyer LA, Lewis JS.

J Nucl Med. 2006 Dec;47(12):2034-41.

17.

Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals.

Ferreira CL, Yapp DT, Lamsa E, Gleave M, Bensimon C, Jurek P, Kiefer GE.

Nucl Med Biol. 2008 Nov;35(8):875-82. doi: 10.1016/j.nucmedbio.2008.09.001.

PMID:
19026949
18.

Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes.

Cutler CS, Wuest M, Anderson CJ, Reichert DE, Sun Y, Martell AE, Welch MJ.

Nucl Med Biol. 2000 May;27(4):375-80.

PMID:
10938473
19.

Production of therapeutic quantities of (64)Cu using a 12 MeV cyclotron.

Obata A, Kasamatsu S, McCarthy DW, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2003 Jul;30(5):535-9.

PMID:
12831992
20.

Rhenium and technetium tricarbonyl complexes anchored by pyrazole-based tripods: novel lead structures for the design of myocardial imaging agents.

Maria L, Cunha S, Videira M, Gano L, Paulo A, Santos IC, Santos I.

Dalton Trans. 2007 Jul 28;(28):3010-9. Epub 2007 Jun 6.

PMID:
17622418

Supplemental Content

Support Center